TransCure bioServices
TransCure bioServices is a leading preclinical research company specializing in humanized mouse models for drug development in oncology, inflammation, infectious diseases, and liver research. With over 12 years of experience, they provide innovative, flexible, and transparent in vivo solutions to accelerate therapeutic discoveries and support collaborations in the biotech and pharma sectors.
Industries
Nr. of Employees
small (1-50)
TransCure bioServices
7 Rue de la Recherche, 75012 Paris, France
Products
CD34+ human immune system mouse model
Mice engrafted with human CD34+ hematopoietic stem cells supporting development of human T, B, NK, myeloid and dendritic compartments for immuno-oncology, infectious disease, and toxicity studies.
Humanized liver mouse model
Animals with human hepatocyte engraftment for modeling hepatotropic infections, hepatotoxicity, NASH, fibrosis and liver-targeted therapeutics.
Double-humanized (immune + liver) mouse model
Combined model containing both a functional human immune system and a humanized liver to assess immune-hepatic interactions, safety and efficacy of liver-targeted immunotherapies.
Conventional immunodeficient and immunocompetent mouse models
Standard rodent models for baseline pharmacology and comparative studies, including immunodeficient hosts for xenograft work.
Oncology panels: CDX and PDX study execution
Provision and execution of studies using cell line-derived xenografts and patient-derived xenografts to test anticancer efficacy and mechanisms.
CD34+ human immune system mouse model
Mice engrafted with human CD34+ hematopoietic stem cells supporting development of human T, B, NK, myeloid and dendritic compartments for immuno-oncology, infectious disease, and toxicity studies.
Humanized liver mouse model
Animals with human hepatocyte engraftment for modeling hepatotropic infections, hepatotoxicity, NASH, fibrosis and liver-targeted therapeutics.
Double-humanized (immune + liver) mouse model
Combined model containing both a functional human immune system and a humanized liver to assess immune-hepatic interactions, safety and efficacy of liver-targeted immunotherapies.
Conventional immunodeficient and immunocompetent mouse models
Standard rodent models for baseline pharmacology and comparative studies, including immunodeficient hosts for xenograft work.
Oncology panels: CDX and PDX study execution
Provision and execution of studies using cell line-derived xenografts and patient-derived xenografts to test anticancer efficacy and mechanisms.
Services
End-to-end support for preclinical programs including study design, bespoke protocol execution, adaptive on-study decisions, in vivo efficacy and safety testing, and data analysis using humanized mouse platforms.
Non-invasive monitoring services including bioluminescence imaging and 3D volumetric tumor imaging for longitudinal assessment of tumor burden and dissemination.
Flow cytometry, local and circulating cytokine quantification, and serum biomarker analyses to support pharmacodynamic, safety, and mechanistic endpoints.
End-to-end support for preclinical programs including study design, bespoke protocol execution, adaptive on-study decisions, in vivo efficacy and safety testing, and data analysis using humanized mouse platforms.
Non-invasive monitoring services including bioluminescence imaging and 3D volumetric tumor imaging for longitudinal assessment of tumor burden and dissemination.
Flow cytometry, local and circulating cytokine quantification, and serum biomarker analyses to support pharmacodynamic, safety, and mechanistic endpoints.
Expertise Areas
- Humanized mouse model development
- Preclinical CRO services and study execution
- Immuno-oncology preclinical research
- Cell and gene therapy (CAR‑T) preclinical evaluation
Key Technologies
- CD34+ human hematopoietic stem cell engraftment
- Humanized liver engraftment
- Double-humanized (immune + liver) animal models
- Patient-derived xenografts (PDX)
News & Updates
Participation in the premier European event dedicated to Cell Therapy innovations, including in vivo engineering and predictive biomarkers.
Participation in a key event for HBV research, showcasing advanced humanized liver mouse models for therapeutic development.
Participation in the major cancer research conference with presentations on humanized mouse models supporting immuno-oncology.
TransCure's CEO Patrick Nef reacts to the Nobel Prize awarded for cancer immunotherapy research, highlighting the importance of humanized mouse models.
Summary of the company's growth, new hires, and expansion of services including new humanized models and collaborations.
Ranked by LES ECHOS in 2020, demonstrating rapid growth and value addition in pharma research services.
Participation in the premier European event dedicated to Cell Therapy innovations, including in vivo engineering and predictive biomarkers.
Participation in a key event for HBV research, showcasing advanced humanized liver mouse models for therapeutic development.
Participation in the major cancer research conference with presentations on humanized mouse models supporting immuno-oncology.
TransCure's CEO Patrick Nef reacts to the Nobel Prize awarded for cancer immunotherapy research, highlighting the importance of humanized mouse models.
Summary of the company's growth, new hires, and expansion of services including new humanized models and collaborations.
Ranked by LES ECHOS in 2020, demonstrating rapid growth and value addition in pharma research services.